Rob Readnour
Managing Director @ Mountain Group Capital
Nashville, United States
Rob Readnour is a Series A investor at Mountain Group Capital in Nashville focused on Biotechnology and AgTech. Rob Readnour is the Managing Director at Mountain Group Partners. He attended the University of Illinois Urbana-Champaign.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Rob Readnour invests in
Stages Rob Readnour invests in
Countries Rob Readnour invests in
Investment Focus
Industry
- Biotechnology 3 (43%)
- AgTech 1 (14%)
- Fertility 1 (14%)
- Veterinary 1 (14%)
- Agriculture 1 (14%)
Stage
- Series A 3 (43%)
- Series B 1 (14%)
- Series C 1 (14%)
- Series E 1 (14%)
- Funding Round 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Verility
|
Verility is developing fertility products that enable us to address the critical demand for the projected need of more meat protein, resulting in improved food sustainability, by helping livestock producers and breeders accelerate reproductive performance through accurate, simple, and cost-effective analysis of animal semen samples at thepoint-of-care as well as ovulation prediction. | $4M / Series A / Jul 27, 2022 | |
TARGAN
|
Applied LifeSciences & Systems is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. ALS-S is developing a solution that revolutionizes current vaccination methods. Our technology will detect, target, and deliver vaccines to each and every chick, ensuring effectivevaccination. This one-of-a-kind accuracy and consistency in the vaccination process boosts the natural immune response to diseases, improves overall flock health, and provides for a cleaner, healthier chick. | $35M / Series C / May 25, 2022 | |
|
TARGAN
|
Applied LifeSciences & Systems is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. ALS-S is developing a solution that revolutionizes current vaccination methods. Our technology will detect, target, and deliver vaccines to each and every chick, ensuring effectivevaccination. This one-of-a-kind accuracy and consistency in the vaccination process boosts the natural immune response to diseases, improves overall flock health, and provides for a cleaner, healthier chick. | $7M / Series B / May 12, 2021 | |
Advanced Animal Diagnostics
|
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed andsimplify production animal research using differential cell counts; and the SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina. | $7M / May 11, 2021 | |
|
Advanced Animal Diagnostics
|
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed andsimplify production animal research using differential cell counts; and the SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina. | $7M / Series E / May 11, 2021 | |
AN2 Therapeutics
|
AN2 Therapeutics, Inc. is a California-based global health biopharmaceutical company focused on modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $12M / Series A / Nov 21, 2019 | |
|
TARGAN
|
Applied LifeSciences & Systems is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. ALS-S is developing a solution that revolutionizes current vaccination methods. Our technology will detect, target, and deliver vaccines to each and every chick, ensuring effectivevaccination. This one-of-a-kind accuracy and consistency in the vaccination process boosts the natural immune response to diseases, improves overall flock health, and provides for a cleaner, healthier chick. | $8M / Series A / Mar 22, 2019 |
Co-Investors
Oval Park Capital
3 deals together
Alexandria Venture Investments
2 deals together
Intersouth Partners
2 deals together
LabCorp Venture Fund
2 deals together
Merck Animal Health Ventures
2 deals together
Murphy Family Ventures
2 deals together
About Mountain Group Capital
Mountain Group Capital invests based on 4 core principles: Invest in the team first, idea second Invest based on business fundamentals, not financial engineering Invest as if you will own the business forever If possible, own the business forever
Mountain Group Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Byron W. Smith
Managing Director
|
|||
Joe Cook III
Managing Director
|
|||
|
Rob Readnour
Managing Director
|
|||
Terry Vance
Advisor
|
|||
Tyler Whitmore
Vice President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Rob Readnour invest in?
Rob Readnour invests primarily in Biotechnology, AgTech and Fertility startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Rob Readnour last invest?
The most recent investment recorded for Rob Readnour closed in Jul 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
